GlobeNewswire

Fortuna reports consolidated financial results for the first quarter 2018

Dela

(All amounts expressed in US dollars, unless otherwise stated)

 

 

 

 

 

VANCOUVER, British Columbia, May 09, 2018 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE:FSM) (TSX:FVI) today reported net income of $13.8 million, EPS of $0.09, and Adjusted EBITDA of $31.8 million in the first quarter of 2018.   

Jorge A. Ganoza, President, CEO and Director, commented, "We are pleased with our results for the first quarter which provide a good start to 2018 with all our key operating and financial indicators reflecting the strength of our assets."  Mr. Ganoza added, "The Company achieved record silver and gold production along with industry leading margins and cash flow generation." Mr. Ganoza concluded, "Fortuna's business strength and liquidity will provide the necessary flexibility to meet funding requirements for the development of the Lindero Project."

First quarter consolidated financial highlights:

  • Sales of $70.4 million compared to $64.8 million in Q1 2017
  • Net income of $13.8 million compared to $13.0 million in Q1 2017
  • EPS of $0.09 compared to $0.08 in Q1 2017
  • Cash flow from operations of $20.1 million and Adjusted EBITDA of $31.8 million compared to $8.9 million and $30.2 million in Q1 2017
  • Cash position, including short term investments, as at March 31, 2018 was $217.3 million
  • Silver and gold production of 2,401,458 and 15,041 ounces, respectively
  • AISC(1) per ounce of payable silver was $2.11

(1) All-in sustaining cash cost is net of by-product credits for gold, lead and zinc

First quarter consolidated financial results

           
Consolidated Metrics   Q1 2018   Q1 2017 % Change
           
Financial (Expressed in $ millions except per share information)
Sales $   70.4  $   64.8 9 %
Mine operating income     31.3     27.2 15 %
Operating income     22.4     19.6 14 %
Net income     13.8     13.0 6 %
           
Earnings per share (basic)     0.09     0.08 13 %
Earnings per share (diluted)     0.09     0.08 13 %
           
Adjusted net income     13.0     14.0 -7 %
Adjusted EBITDA     31.8     30.2 5 %
Cash provided by operating activities     20.1     8.9 126 %
Cash generated by operating activities before changes in working capital     15.2     15.6 -3 %
Capex (sustaining)     4.1     5.1 -19 %
Capex (non-sustaining)     4.9     1.9 157 %
Capex (Brownfield)     2.3     2.7 -17 %
AISC1     2.1     6.1 -65 %
           
    Mar 31, 2018   Dec 31, 2017 % Change
Cash, cash equivalents, and short-term investments $   217.3  $   212.6 2 %
           
Total assets $   707.5  $   706.6 0 %
Non-current bank loan $   39.6  $   39.9 -1 %

Net income for the three months ended March 31, 2018 was $13.8 million or $0.09 per share compared to $13.0 million or $0.08 per share for the comparable quarter in 2017.  Higher sales of 9% over the comparable quarter resulted in turn in higher operating income of 14% which was partially offset at the net income level by a higher income tax expense.  The effective tax rate for the first quarter 2018 was 38% compared to 26% for the same quarter in 2017.  The low effective tax rate in 2017 was due to a high inflation rate and a strong Mexican Peso against the US dollar in Q1 2017 which have a positive impact on our Mexican operation, and lowered the income tax expense.

Adjusted net income was $13.0 million compared to $14.0 million in 2017, a decrease of $1.0 million after adjusting for unrealized gains on lead and zinc derivative contracts. 

Silver and gold sold were 7% and 9% lower than actual metal produced reflecting higher concentrate inventory at the end of the first quarter associated with a change in our sales contract at the San Jose mine in the first quarter which involves a shift from local delivery of the concentrates to export of concentrate.  This increased our concentrate inventory 618 tonnes with an estimated value of $4.1 million.  The delay in the recognition of this sale would have contributed approximately $2.7 million to pre-tax earnings or $0.01 per share after tax.

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/ea037562-3817-4597-a0fe-b8f60f97c76a

Adjusted EBITDA in the first quarter of 2018 increased $1.6 million over the prior year to $31.8 million as higher sales of $5.6 million over the comparable period in 2017 were partially offset by increases of $1.5 million in mine operating costs, $0.8 million in mine selling, general and administration costs, $1.3 million in share-based payment expense and $1.0 million in realized losses from commodity derivative contracts.

Cash provided by operating activities was $20.1 million or 126% higher than the $8.9 million for the same period in 2017.

As at March 31, 2018, the Company had cash and short-term investments of $217.3 million (December 31, 2017: $212.6 million).  On January 26, 2018 the Company closed an amendment to its existing credit facility with Scotiabank to expand the facility from $40.0 million to $120.0 million.  This takes our total sources of liquidity as at the end of the quarter to over $290.0 million which along with the current rate of free cash flow generated from our existing operations should provide sufficient liquidity to meet our funding needs during the construction of the Lindero project.

San Jose Mine, Mexico

               
      Three months ended March 31,    
Mine Production     2018        2017    
Tonnes milled     258,204       267,268    
Average tonnes milled per day                                                                  3,011       3,108    
               
Silver              
  Grade (g/t)     284       226    
  Recovery (%)     93       92    
  Production (oz)     2,185,913       1,792,967    
  Metal sold (oz)     2,011,260       1,779,203    
  Realized price ($/oz)     16.65       17.46    
               
Gold              
  Grade (g/t)     1.94       1.67    
  Recovery (%)     92       91    
  Production (oz)     14,882       13,116    
  Metal sold (oz)     13,748       13,040    
  Realized price ($/oz)     1,329       1,220    
               
Unit Costs              
  Production cash cost ($/oz Ag)1     -0.33       1.34    
  Production cash cost ($/t)     65.26       56.85    
  Unit Net Smelter Return ($/t)     203.81       161.75    
  All-in sustaining cash cost ($/oz Ag)1     4.03       6.60    
               
1 Net of by-product credits from gold              
               

The San Jose Mine produced 2,185,913 ounces of silver and 14,882 ounces of gold in the first quarter of 2018 which were 22% and 13% above the comparable period in 2017.  Average head grades for silver and gold were 284 g/t and 1.94 g/t which were 25% and 16% higher than the comparable period in 2017.

Cash cost per tonne of processed ore was $65.3, or 15% above the $56.9 cash cost for the comparable quarter in 2017 and 7% above annual guidance of $61.2.  The higher cost compared to guidance was due to one-time items related to the operations of the dry stack tailings facility ($3.4/tonne), higher transportation costs due to increased shipments ($2.4/tonne) and faster execution of community relations program ($1.5/tonne).  Cash cost per tonne for the remainder of the year is expected to be in line with guidance.

All-in sustaining cash cost per payable ounce of silver, net of by-product credits, was $4.0 for first quarter of 2018 and was below the annual guidance of $6.6 as a result of lower execution on sustaining capital and improvements in concentrate commercial terms.

Caylloma Mine, Peru

             
      Three months ended March 31,  
Mine Production     2018        2017  
Tonnes milled     129,620       129,369  
Average tonnes milled per day                                                              1,473       1,470  
             
Silver            
  Grade (g/t)     61       68  
  Recovery (%)     84       85  
  Production (oz)     215,545       240,224  
  Metal sold (oz)     220,290       236,068  
  Realized price ($/oz)     16.79       17.33  
             
Lead            
  Grade (%)     2.72       2.76  
  Recovery (%)     91       92  
  Production (000's lbs)     7,040       7,211  
  Metal sold (000's lbs)     7,269       7,037  
  Realized price ($/lb)     1.14       1.03  
             
Zinc            
  Grade (%)     4.31       4.17  
  Recovery (%)     90       91  
  Production (000's lbs)     11,028       10,816  
  Metal sold (000's lbs)     11,078       10,702  
  Realized price ($/lb)     1.55       1.26  
             
Unit Costs            
  Production cash cost ($/oz Ag)1     (54.08 )     (31.54 )
  Production cash cost ($/t)     78.68       73.30  
  Unit Net Smelter Return ($/t)     190.33       158.92  
  All-in sustaining cash cost ($/oz Ag)1     (31.36 )     (11.97 )
             
1 Net of by-product credits from gold, lead and zinc

Quarterly Results

The Caylloma Mine produced 7.0 million pounds of lead and 11.0 million pounds of zinc which were 2% below and 2% above the comparable quarter in 2017.  Average head grades for lead and zinc were 2.72% and 4.31%.  Silver production was 215,545 ounces which was 10% lower than the comparable period in 2017 and average silver head grade was 10% lower than in 2017.  Metallurgical recovery was 84% or 1% lower than in 2017. 

Cash cost per tonne of processed ore for the first quarter of 2018 was $78.7, which was 7% higher than the $73.3 cash cost for the comparable quarter in 2017 and 3% below annual guidance of $81.3.  

All-in sustaining cash cost per payable ounce of silver, net of by-product credits, was a negative $31.4 for the first quarter 2018 which was significantly below the annual guidance of a negative $5.2 as a result of higher by-product credits.

Reconciliation to Adjusted Net Income

  Q1 2018 Adjustments Q1 2018 
adjusted
Q1 2017 Adjustments Q1 2017 
adjusted
Sales   70.4       70.4     64.8       64.8  
Cost of sales   39.1       39.1     37.7       37.7  
Mine operating income   31.3     -     31.3     27.2     -     27.2  
Selling, general and administration   6.9       6.9     5.3       5.3  
Exploration and evaluation   0.1       0.1     0.1       0.1  
Share of loss of equity-accounted investee   (0.2 )   0.2     -     0.1     (0.1 )   -  
Foreign exchange loss (gain)   2.2       2.2     2.1       2.1  
Operating Income   22.3     (0.2 )   22.1     19.6     0.1     19.7  
Interest income   (0.6 )     (0.6 )   (0.3 )     (0.3 )
Interest expense   0.5       0.5     0.5       0.5  
Other finance items   0.4     (0.4 )   -     -       -  
Accretion of provisions   0.2       0.2     0.2       0.2  
(Gain) loss on financial assets and liabilities carried at fair value   (0.4 )   1.4     1.0     1.6     (0.6 )   1.0  
Income before taxes   22.3     (1.2 )   21.1     17.6     0.7     18.3  
Current income tax expense   9.7     (0.4 )   9.3     8.0     (0.3 )   7.7  
Deferred income tax recovery   (1.2 )     (1.2 )   (3.4 )     (3.4 )
Net income for the year   13.8     (0.8 )   13.0     13.0     1.0     14.0  
EPS 0.09   (0.00 ) 0.09   0.08   0.00   0.08  

The financial statements and MD&A are available on SEDAR and have also been posted on the company's website at https://www.fortunasilver.com/investors/financials/2018/.     

Conference call to review first quarter 2018 financial and operational results

A conference call to discuss first quarter 2018 financial and operational results will be held on Thursday, May 10, 2018 at 9:00 a.m. Pacific | 12:00 p.m. Eastern. Hosting the call will be Jorge A. Ganoza, President and CEO, and Luis D. Ganoza, Chief Financial Officer.

Shareholders, analysts, media and interested investors are invited to listen to the live conference call by logging onto the webcast at: http://www.investorcalendar.com/IC/CEPage.asp?ID=176642 or over the phone by dialing just prior to the starting time.

Conference call details:
Date: Thursday, May 10, 2018
Time: 9:00 a.m. Pacific | 12:00 p.m. Eastern

Dial in number (Toll Free): +1.877.407.8035
Dial in number (International): +1.201.689.8035

Replay number (Toll Free): +1.877.481.4010
Replay number (International): +1.919.882.2331
Replay Passcode: 10450

Playback of the conference call will be available until May 24, 2018 at 11:59 p.m. Eastern. Playback of the webcast will be available until August 10, 2018. In addition, a transcript of the call will be archived in the company's website: https://www.fortunasilver.com/investors/financials/2018/.    

About Fortuna Silver Mines Inc.

Fortuna is a growth oriented, precious metal producer focused on mining opportunities in Latin America. The Company's primary assets are the Caylloma silver mine in southern Peru, the San Jose silver-gold mine in Mexico and the Lindero gold project in Argentina. The Company is selectively pursuing acquisition opportunities throughout the Americas and in select other areas.

ON BEHALF OF THE BOARD

Jorge A. Ganoza 
President, CEO and Director
Fortuna Silver Mines Inc.

Trading symbols: NYSE: FSM | TSX: FVI

Investor Relations:

Carlos Baca- T (Peru): +51.1.616.6060, ext. 0

Forward Looking Statements

This news release contains forward looking statements which constitute "forward looking information" within the meaning of applicable Canadian securities legislation and "forward looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (collectively, "Forward looking Statements"). All statements included herein, other than statements of historical fact, are Forward Looking Statements and are subject to a variety of known and unknown risks and uncertainties which could cause actual events or results to differ materially from those reflected in the Forward Looking Statements. The Forward Looking Statements in this news release include, without limitation, statements about the Company's plans for its mines and mineral properties; the Company's business strategy, plans and outlook; the merit of the Company's mines and mineral properties; the future financial or operating performance of the Company; and proposed expenditures. Often, but not always, these Forward Looking Statements can be identified by the use of words such as "estimated", "potential", "open", "future", "assumed", "projected", "used", "detailed", "has been", "gain", "planned", "reflecting", "will", "containing", "remaining", "to be", or statements that events, "could" or "should" occur or be achieved and similar expressions, including negative variations.

Forward looking Statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any results, performance or achievements expressed or implied by the Forward Looking Statements. Such uncertainties and factors include, among others, changes in general economic conditions and financial markets; changes in prices for silver and other metals; technological and operational hazards in Fortuna's mining and mine development activities; risks inherent in mineral exploration; uncertainties inherent in the estimation of mineral reserves, mineral resources, and metal recoveries; governmental and other approvals; political unrest or instability in countries where Fortuna is active; labor relations issues; as well as those factors discussed under "Risk Factors" in the Company's Annual Information Form. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in Forward Looking Statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

Forward looking Statements contained herein are based on the assumptions, beliefs, expectations and opinions of management, including but not limited to expectations regarding the Company's plans for its mines and mineral properties; mine production costs; expected trends in mineral prices and currency exchange rates; the accuracy of the Company's current mineral resource and reserve estimates; that the Company's activities will be in accordance with the Company's public statements and stated goals; that there will be no material adverse change affecting the Company or its properties; that all required approvals will be obtained; that there will be no significant disruptions affecting operations and such other assumptions as set out herein. Forward looking Statements are made as of the date hereof and the Company disclaims any obligation to update any Forward Looking Statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that Forward Looking Statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, investors should not place undue reliance on Forward Looking Statements.

This news release also refers to non-GAAP financial measures, such as cash cost per tonne of processed ore; cash cost per payable ounce of silver; total production cost per tonne; all-in sustaining cash cost; all-in cash cost; adjusted net (loss) income; operating cash flow per share before changes in working capital, income taxes, and interest income; and adjusted EBITDA. These measures do not have a standardized meaning or method of calculation, even though the descriptions of such measures may be similar. These performance measures have no meaning under International Financial Reporting Standards (IFRS) and therefore, amounts presented may not be comparable to similar data presented by other mining companies.





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Fortuna Silver Mines Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum